Apotex Plavix Saga May Finally Be Over; Judge Asks “What Is Going On In This Case?”
This article was originally published in The Pink Sheet Daily
Apotex sought $3.4 billion in damages, claiming Bristol-Myers Squibb scuttled their patent settlement agreement by submitting a false certification to the FTC that it had no oral commitment not to sell an authorized generic of Plavix during Apotex’s exclusivity period; Apotex had told the FTC there was such a side deal.
You may also be interested in...
The high court will determine whether brand-generic reverse payments to settle patent disputes are presumptively anticompetitive and unlawful when it takes up FTC v. Actavis; a ruling affirming the lower court would enable companies to enter agreements without the threat of litigation.
A judge sets damages at 50% of Apotex's net sales of generic clopidogrel plus prejudgment interest of $107.9 million.
Former Bristol-Myers Squibb executive Andrew Bodnar may have escaped jail time for lying to the Federal Trade Commission, but he may suffer, nonetheless. Publishers and authors say his unusual sentence to write a book about his experience will bring plenty of pain and humiliation